准广泛耐药结核患者中罕见gyrA和rpoB突变菌群的群体动力学提示上位性互作
本文报告一例准广泛耐药结核患者在治疗期间因间断自行停药出现对利福平和左氧氟沙星的异质性耐药,应用全基因组测序分析5对痰分离株的宿主内菌群构成。携带罕见rpoB V170F和gyrA S91P突变的亚克隆在含左氧氟沙星不含利福平的治疗中7天内快速成为优势菌,随后出现rpoC V483A补偿突变并占主导。
要点
- 治疗不规律可导致准广泛耐药结核患者出现异质性耐药和亚克隆更替。
- 罕见rpoB V170F与gyrA S91P突变亚克隆可在7天内快速成为优势群体。
- rpoB V170F后出现rpoC V483A补偿突变并占主导,提示突变间上位性互作。
核心结论
- 这是首次报道的准广泛耐药结核患者在治疗期间出现罕见突变亚克隆并在宿主内成为优势群体的病例。
研究设计与样本
- 病例报告,对一例准广泛耐药结核患者治疗期间的5对痰分离株进行全基因组测序以分析宿主内菌株组成。
主要发现
- 该亚克隆携带利福平耐药罕见突变rpoB V170F和左氧氟沙星耐药罕见突变gyrA S91P。
- 在含左氧氟沙星但不含利福平的治疗期间,该亚克隆在7天内快速竞争超过其他亚克隆。
- rpoB V170F突变后出现高概率补偿突变rpoC V483A并成为优势。
临床怎么用
- 对治疗不规律、疗效不佳的耐药结核患者应警惕异质性耐药和亚克隆演化。
- 必要时结合全基因组测序评估宿主内菌群构成和补偿突变。
局限性
- 仅为单例病例报告,结论的外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Bacterial population kinetics of strains harbouring drug resistance-conferring mutations within a patient often show cryptic resistance in clinical practice. We report a case that showed emergence and dominance of Mycobacterium tuberculosis with uncommon rpoB and gyrA mutations, followed by an rpoC compensatory mutation, during treatment. METHODS: A pre-XDR-TB patient showed heteroresistance to rifampicin and levofloxacin during treatment as a result of intermittent self-cessation. WGS was applied to investigate intra-host strain composition using five pairs of isolates from sputum samples. RESULTS: The subclone in this study possessed rare mutations conferring resistance to rifampicin (rpoB V170F) and levofloxacin (gyrA S91P) and it rapidly outcompeted other subclones during treatment that included levofloxacin but not rifampicin (<7 days). The high-probability compensatory mutation rpoC V483A also emerged and became dominant subsequent to the rpoB V170F mutation. CONCLUSIONS: To the best of our knowledge, this is the first case showing the emergence of such a rare variant that dominated the population within a patient during treatment of TB.
引用
- Yoshida S, Iwamoto T, Arikawa K, et al. Bacterial population kinetics in heteroresistant Mycobacterium tuberculosis harbouring rare resistance-conferring mutations in gyrA and rpoB imply an epistatic interaction of mutations in a pre-XDR-TB patient. J Antimicrob Chemother. 2020. PMID: 32303065. doi:10.1093/jac/dkaa109
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。